Renovaro Inc. Files 2024 10-K

TL;DR

Renovaro Inc. (formerly Enochian Biosciences) filed its 2024 10-K, detailing its financial status and business operations.

AI Summary

Renovaro Inc. filed its 10-K for the fiscal year ending June 30, 2024, reporting its financial performance and business operations. The company, formerly known as Enochian Biosciences Inc. and Renovaro Biosciences Inc., is involved in the pharmaceutical preparations industry. Its principal executive offices are located in Los Angeles, California.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Renovaro Inc.'s financial health and strategic direction for the fiscal year 2024, including any significant changes or developments.

Risk Assessment

Risk Level: medium — As a pharmaceutical preparations company, Renovaro Inc. faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 2024-06-30 — Fiscal Year End (The period covered by the 10-K filing.)
• 2024-10-10 — Filing Date (The date the 10-K was submitted to the SEC.)

Key Players & Entities

• Renovaro Inc. (company) — Filer of the 10-K
• Enochian Biosciences Inc. (company) — Former name of Renovaro Inc.
• Renovaro Biosciences Inc. (company) — Former name of Renovaro Inc.
• 2024-06-30 (date) — Fiscal year end for the 10-K filing
• 2024-10-10 (date) — Filing date of the 10-K
• Los Angeles, CA (location) — Location of Renovaro Inc.'s business address

FAQ

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar

Filing Documents

• e5986_10-k.htm (10-K) — 1992KB
• e5986_ex10-10.htm (EX-10.10) — 116KB
• e5986_ex21-1.htm (EX-21.1) — 4KB
• e5986_ex23-1.htm (EX-23.1) — 3KB
• e5986_ex31-1.htm (EX-31.1) — 14KB
• e5986_ex31-2.htm (EX-31.2) — 14KB
• e5986_ex32-1.htm (EX-32.1) — 6KB
• e5986_ex32-2.htm (EX-32.2) — 5KB
• image_002.jpg (GRAPHIC) — 41KB
• image_003.jpg (GRAPHIC) — 41KB
• 0001731122-24-001578.txt ( ) — 9951KB
• renb-20240630.xsd (EX-101.SCH) — 74KB
• renb-20240630_cal.xml (EX-101.CAL) — 64KB
• renb-20240630_def.xml (EX-101.DEF) — 311KB
• renb-20240630_lab.xml (EX-101.LAB) — 541KB
• renb-20240630_pre.xml (EX-101.PRE) — 471KB
• e5986_10-k_htm.xml (XML) — 1414KB

Business

Business 1 Item 1A

Risk Factors

Risk Factors 21 Item 1B Unresolved Staff Comments 54 Item 1C Cybersecurity Risk Management and Strategy 54 Item 2

Properties

Properties 55 Item 3

Legal Proceedings

Legal Proceedings 55 Item 4 Mine Safety Disclosures 57 Part II 57 Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 57 Item 6 Selected Financial Data 58 Item 7 Management's Discussion and Analysis of Financial Condition and Results Of Operations 58 Item 7A Quantitative and Qualitative Disclosures About Market Risk 70 Item 8 Financial 70 Item 9 Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 71 Item 9A Controls and Procedures 71 Item 9B Other Information 72 Part III 72 Item 10 Directors, Executive Officers and Corporate Governance 72 Item 11 Executive Compensation 72 Item 12 Security 72 Item 13 Certain Relationships and Related Transactions and Director Independence 72 Item 14 Principal Accountant Fees and Services 72 Part IV 73 Item 15 Exhibits, Financial Statement Schedules 73

Signatures

Signatures and Certifications 77 i Cautionary Language Regarding Forward-Looking Statements and Industry Data This Annual Report on Form 10-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the plans and objectives of management for future operations and market trends and expectations. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking "intend," "plan," "anticipate," "believe," "approximately," "estimate," "predict," "project," "potential" or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking.

Forward-looking statements include,

Forward-looking statements include, but are not limited to, statements concerning: Our ability to continue as a going concern and ability to raise additional capital; Our continuous incurrence of losses as a pre-clinical-stage biotechnology company with no products that have achieved regulatory approval; Our ability to generate revenue if we fail to develop marketable product; Our dependence on substantial additional financing to support the research, development, licensing, manufacture, and marketing of product candidates and products, and the possibility that unforeseen operational costs will arise; The dilutive effect on stockholders' ownership interests of the Company raising capital through an equity issuance in connection with future equity financing or equity debt agreements; Our dependence on the services of experts, including third parties to research and develop product candidates in cooperation with our employees and officers; The difficulty or impossibility of predicting future clinical trial results and regulatory outcomes of our products based upon our pre-clinical or earlier clinical trial performance; The application of heightened regulatory and commercial scrutiny to our AI-based technology, gene, cell, and immunotherapy products given their novel nature and concomitant potential for actual or perceived safety issues; Our ability to compete in rapidly developing fields, and the potential impact to our financial condition, product marketability, and operational capacities of a competitor receiving regulatory approval before us, or a competitor developing more advanced or efficacious products; Potential delays or total failures of third parties, such as universities, non-profits, and clinical research centers, to perform obligations on which our product research and development rely; The impact on our competitive position, business operations, and financial condition of implementation of amended healthcare laws and regulations;

View Full Filing

View this 10-K filing on SEC EDGAR